Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor
cells by stopping blood flow to the tumor. It is not yet known whether giving docetaxel
together with bevacizumab is more effective than docetaxel alone in treating breast cancer.
PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with
bevacizumab works compared to docetaxel alone as first-line therapy in treating women with
stage IV breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Oncology Research International
Collaborators:
National Cancer Institute (NCI) University of California, Los Angeles